Clinical Experience With Peregrine's Anti-Cancer Agent Bavituximab... - "I look forward to helping to advance the clinical program for this novel approach to cancer therapy." Peregrine Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing monoclonal antibodies for the trea ent of cancer and hepatitis C virus infection , today reported that clinical data on ... via Freshnews
Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2008 - Peregrine Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today announced financial results for ... via Med Ad News
Peregrine Pharmaceuticals Announces Positive Data From Cotara(R) Brain Cancer Trials - "We are encouraged by early results from these two Cotara clinical studies and look forward to presenting data from the dosimetry trial at the upcoming ASCO Annual Meeting" Main Category: Neurology / Neuroscience Also Included In: Cancer / Oncology ; Clinical Trials / Drug Trials ; Pharma Industry / Biotech Industry Article Date: 12 Mar 2008 - 0:00 PDT newsletters Peregrine ... via Medical News Today
Peregrine awarded two patents - Peregrine Pharmaceuticals Inc. has been issued two new U.S. patents in the field of targeted anti-aminophospholipid agents, the company said Monday.
TUSTIN--- Peregrine Pharmaceuticals Receives 180-DAY Extension From... - "We intend to work diligently over the coming months to ensure that we maintain our listing on the Nasdaq Stock Market." Peregrine Pharmaceuticals, Inc. , a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus infection, today announced that it has received a ... via Freshnews
|
|
|